Scenarios of a post-antibiotic society are dire and include massive, highly preventable loss of life, widening socio-economic disparities, and significant economic shortfalls. Estimates of the potential economic impact of antimicrobial resistance (AMR) could be as large as a global annual GDP shortfall of nearly $3.4 trillion by 2030 and $7 trillion by 2050.[i] Currently, 700,000 people die every year due to drug-resistant infections globally.[ii]
Amid the backdrop of the 72nd United Nations General Assembly (UNGA), USP introduced its Quality Institute – a center that will conduct much-needed research to foster evidence-based policy decisions that can help increase the availability of quality-assured medicines worldwide.
Today, two billion people – more than 25% of the world’s population – benefit from the quality standards we develop with our partners for how medicines, dietary supplements, and food are produced. These standards help build a foundation for quality that makes the world a safer and healthier place. Click here to read more.
The bipartisan support for the Pharmacy and Medically Underserved Areas Enhancement Act demonstrates that legislators and policymakers recognize the value pharmacists bring to patients and the U.S. healthcare system. USP applauds this step and supports swift passage of this important legislation.
Legislation being considered by Congress will remove the requirement that all biologic medicines – drugs such as insulin, vaccines, cancer treatments and other therapies made using living matter – comply with public quality standards of the U.S. Pharmacopeia (USP). This same legislation would also apply to biosimilars. As a result, public confidence in biologics and biosimilars as well as patient safety would be at risk. Learn more.